Vivo Bio TechBOM:511509 -1.41%68 EBITDA Margin % is 31.54% as of Mar. 2026, which is 3% below its 10-year median of 32.62. GuruFocus rates BOM:511509 with a GF Score™ of 68/100 and a GF Value™ of ₹29.55 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Vivo Bio Tech ranks better than 92.06% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vivo Bio Tech's EBITDA for the
three
months ended in Mar. 2026 was ₹44.8 Mil. Vivo Bio Tech's Revenue for the
three
months ended in Mar. 2026 was ₹142.0 Mil. Therefore, Vivo Bio Tech's EBITDA margin for the quarter that ended in Mar. 2026 was 31.54%.
Vivo Bio Tech (BOM:511509) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vivo Bio Tech EBITDA Margin % Related Terms
Vivo Bio Tech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vivo Bio Tech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:511509 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Vivo Bio Tech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivo Bio Tech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivo Bio Tech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vivo Bio Tech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivo Bio Tech (BOM:511509) has a EBITDA Margin % of 31.54% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vivo Bio Tech and its competitors. This is near median its historical median of 32.62. Over the past decade, Vivo Bio Tech's EBITDA Margin % has ranged from 17.06 to 54.24. According to the industry distribution chart, Vivo Bio Tech ranks #75 out of 944 companies in the Biotechnology industry, placing it in the top 7.9%.
Is Vivo Bio Tech's EBITDA Margin % too high?
Vivo Bio Tech's current EBITDA Margin % of 31.54% is near median its 10-year median of 32.62. Over the past 10 years, this metric has ranged from a low of 17.06 to a high of 54.24. Based on the distribution chart, Vivo Bio Tech ranks #75 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vivo Bio Tech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vivo Bio Tech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vivo Bio Tech ranks #75 out of 944 companies for EBITDA Margin %. This places Vivo Bio Tech in the top 8% of its industry — outperforming the majority of peers. Historically, Vivo Bio Tech's own EBITDA Margin % has ranged from 17.06 to 54.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vivo Bio Tech and its competitors. Vivo Bio Tech's current EBITDA Margin % is 31.54%, which is near median its own 10-year median of 32.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivo Bio Tech stock overvalued right now?
Based on GuruFocus' analysis, Vivo Bio Tech (BOM:511509) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹29.55, compared to a current price of ₹23.04 — trading 22% below its estimated fair value. The current EBITDA Margin % is 31.54%, which is near median its 10-year median of 32.62. Vivo Bio Tech's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vivo Bio Tech (BOM:511509), the current EBITDA Margin % is 31.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivo Bio Tech (BOM:511509) Overvalued in 2026?
Based on GuruFocus' analysis, Vivo Bio Tech stock appears to be undervalued.
The current stock price of ₹23.04 is trading 22% below its estimated GF Value™ of ₹29.55.
GuruFocus considers Vivo Bio Tech to be Modestly Undervalued.
Key valuation signals for BOM:511509:
EBITDA Margin %: 31.54% (near median its 10-year median of 32.62)
GF Value™: ₹29.55 vs. price of ₹23.04 (22% below fair value)
No single metric tells the full story. See the BOM:511509 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivo Bio Tech Ltd offers drug development and discovery services to pharmaceutical and biotech companies. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies. It offers services in the areas of pharmacology, toxicology, pathology, analytical chemistry, lab animal diagnostics, custom model generation, custom breeding, surgical models, and molecular biology.
68GF Score
Get the complete analysis for BOM:511509
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:511509 has been successfully added to your 
